Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure.
High PTH levels have been reported in patients with chronic heart failure (CHF). Similarly, its levels increase with aging and are related to impaired survival in elderly adults. However, its relationship with neuroendocrine activation and endothelial dysfunction in CHF has not been previously studied. Seventy-three CHF males with New York Heart Association (NYHA) classes II and III and 20 control subjects aged ≥ 55 yr were recruited. PTH, 25-hydroxyvitamin D [25(OH)D], N-terminal pro-brain natriuretic peptide (NT-pro-BNP), adiponectin, and osteoprotegerin were measured. Endothelial function (brachial flow mediated dilation), echocardiography, physical performance, and quality of life were assessed, as well. CHF patients had markedly increased serum PTH (77 ± 33 vs 40 ± 11 pg/ml, p<0.0001), NT-pro-BNP [1809 (2742) vs 67 (74) pg/ml, p<0.0001], adiponectin (17 ± 9 vs 10 ± 2 μg/ml, p<0.0001), osteoprotegerin, whereas 25(OH)D levels were decreased compared to controls. Increased PTH is positively correlated with NTpro- BNP (r=0.399, p<0.0001), adiponectin (r=0.398, p<0.0001), and osteoprotegerin, whereas negatively with 25(OH)D in CHF patients. Additionally, increased serum PTH was associated with endothelial dysfunction, echocardiographic variables of heart failure progression, impaired physical performance, and deteriorated quality of life. In a multivariate linear regression analysis, increased serum PTH was independently associated with neuroendocrine activation (NT-pro-BNP, adiponectin) and endothelial dysfunction in elderly CHF men (R2=0.455). Additionally, demonstrated relations with other well-established variables of heart failure severity suggest the potential role of serum PTH in the pathogenesis and non-invasive monitoring of heart failure progression. Future studies are needed to evaluate the predictive value of serum PTH for clinical outcomes as well as beneficial potential of PTH suppression in CHF patients.
Loncar
G
G
Cardiology Department, Clinical Medical Center Zvezdara, Belgrade, Serbia.
Bozic
B
B
Dimkovic
S
S
Prodanovic
N
N
Radojicic
Z
Z
Cvorovic
V
V
Putnikovic
B
B
Popovic
V
V
D052242:Adiponectin / Q000097:blood; D000368:Aged; D002908:Chronic Disease; D004730:Endothelium, Vascular / Q000503:physiopathology*; D006333:Heart Failure / Q000097:blood* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009490:Neurosecretory Systems / Q000502:physiology*; D053244:Osteoprotegerin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood; D012372:ROC Curve; D014652:Vascular Diseases / Q000097:blood / Q000503:physiopathology; D014807:Vitamin D / Q000097:blood
D052242:Adiponectin; D053244:Osteoprotegerin; D010281:Parathyroid Hormone; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D014807:Vitamin D
JAMA. 1993 Oct 13;270(14):1702-7
8411500
Heart. 1999 Dec;82 Suppl 4:IV8-IV10
10574904
N Engl J Med. 2002 Oct 31;347(18):1397-402
12409541
J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
11788217
J Intern Med. 2009 Apr;265(4):488-95
19019181
Heart Fail Rev. 2006 Mar;11(1):45-55
16819577
Circ J. 2009 Jun;73(6):1012-3
19465781
Circulation. 1994 Dec;90(6):2772-9
7994820
Cardiovasc Res. 2009 Apr 1;82(1):77-83
19168854
J Clin Endocrinol Metab. 2008 Oct;93(10):3927-35
18682515
Circulation. 2005 Jan 25;111(3):310-4
15655134
Am Heart J. 1992 Oct;124(4):1017-25
1529875
Int J Cardiol. 2004 Apr;94(2-3):283-7
15093994
Cell. 2007 Aug 10;130(3):456-69
17693256
Circulation. 1997 Jul 15;96(2):526-34
9244221
N Engl J Med. 2008 May 15;358(20):2148-59
18480207
Hypertension. 2007 Jun;49(6):1392-8
17470718
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
12091180
Clin Endocrinol (Oxf). 1999 Aug;51(2):217-21
10468993
Clin Med Res. 2007 Dec;5(4):238-43
18367709
Eur Heart J. 2003 Nov;24(22):2054-60
14613742
Clin Endocrinol (Oxf). 2008 Jul;69(1):29-35
18208576
J Am Coll Cardiol. 2004 Nov 16;44(10):1970-6
15542278
Clin Nephrol. 2004 Mar;61(3):177-84
15077868
Mol Cell Endocrinol. 2009 Oct 30;310(1-2):21-9
19376193
Diabetes Care. 2006 Jul;29(7):1664-6
16801598
Circulation. 2005 Feb 22;111(7):871-8
15710759
Circ J. 2007 May;71(5):623-30
17456982
Am J Med. 1997 Sep;103(3):197-207
9316552
Nephron. 1976;16(1):31-41
1244564
Radiology. 1982 Apr;143(1):29-36
7063747
Heart. 2009 Mar;95(5):395-8
19001003
Circulation. 1997 Sep 2;96(5):1416-23
9315526
J Am Coll Cardiol. 2003 Jan 1;41(1):105-12
12570952
Gerontology. 2009;55(4):405-10
19571528
Prog Cardiovasc Dis. 1994 Jan-Feb;36(4):309-42
8284434
Cardiology. 2008;111(1):51-6
18239393
Clin Chim Acta. 2006 Apr;366(1-2):27-36
16313895
Trends Endocrinol Metab. 2004 Mar;15(2):60-5
15036251
Med Hypotheses. 2005;64(5):1022-6
15780504
J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80
17996563
J Am Soc Echocardiogr. 2009 Mar;22(3):213-31; quiz 316-7
19258174
Eur Heart J. 2005 Jan;26(1):65-9
15615801
Heart. 2006 Oct;92(10):1420-4
16621874